Traditional Chinese Medicine Enema Therapy in a Patient With a Confirmed Negative SARS-CoV-2 Test in the Respiratory Tract but Positive in the Intestinal Tract: A Case Report

Abstract

We report the case of a 43-year-old man who was infected with SARS-CoV-2 in February 2020 and actively cooperated with treatment in the hospital. During the course of treatment, we found that the respiratory SARS-CoV-2 nucleic acid became negative, but remained positive in the intestinal tract. As a result, we adjusted the treatment plan to include traditional Chinese medicine enema treatment. The patient had negative intestinal SARS-CoV-2 nucleic acid test within 4 days, and the subsequent repeated review of intestinal SARS-CoV-2 nucleic acid was negative, and the virus was undetectable. It is suggested that traditional Chinese medicine enema treatment may be helpful to remove the SARS-CoV-2 in the intestines of patients with COVID-19 infection, and may support the treatment of patients with respiratory SARS-CoV-2 nucleic acid negative and positive in the intestinal tract.

Integrated therapeutic plasma exchange and traditional Chinese medicine treatment in a patient with severe COVID-19: A case report

“…Additionally, similar case reports published on PubMed have also been reviewed by us, and most of them follow the guidelines mentioned above. Our case report also followed this recommendation, by using the TCM recommended in the guidelines and following the principle of syndrome differentiation [36] , [37] , [38] , [39] .…”

Organoids to Remodel SARS-CoV-2 Research: Updates, Limitations and Perspectives

“…Further studies are needed to verify this finding [ 136 , 137 ]. In a case report, enema treatments with traditional Chinese medicine were shown to inhibit the spread of SARS-CoV-2 in the intestine, curing intestinal symptoms and preventing faecal-oral transmission [ 138 ]. In conclusion, only remdesivir has been demonstrated to be effective against intestinal symptoms and in the control of SARS-CoV-2 infection; famotidine might benefit critical patients, whereas more evidence is required for the effectiveness of other novel drugs.…”